Buscar
Journey Medical Corp
DERMAñadir a la lista de seguimiento
7.090USD
+0.050+0.71%
Cierre 07/02, 13:00（ET）Cotizaciones retrasadas 15 min
192.46MCap. mercado
PérdidaP/E TTM
Más Datos de Journey Medical Corp Compañía
Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.
Información de Journey Medical Corp
Símbolo de cotizaciónDERM
Nombre de la empresaJourney Medical Corp
Fecha de salida a bolsaNov 12, 2021
Director ejecutivoMaraoui (Claude)
Número de empleados41
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 12
Dirección9237 E Via De Ventura Blvd., Suite 105
CiudadSCOTTSDALE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal85258
Teléfono14804346670
Sitio Webhttps://journeymedicalcorp.com/
Símbolo de cotizaciónDERM
Fecha de salida a bolsaNov 12, 2021
Director ejecutivoMaraoui (Claude)
Ejecutivos de Journey Medical Corp
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Claude Maraoui
Mr. Claude Maraoui
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.29M
+10.02%
Mr. Ramsey Alloush
Mr. Ramsey Alloush
Chief Operating Officer, General Counsel
Chief Operating Officer, General Counsel
470.73K
+32.73%
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
330.44K
-14.36%
Mr. Joseph Benesch, CPA
Mr. Joseph Benesch, CPA
Chief Financial Officer, Corporate Controller
Chief Financial Officer, Corporate Controller
187.57K
+46.27%
Mr. Neil Herskowitz
Mr. Neil Herskowitz
Independent Director
Independent Director
81.44K
-21.42%
Ms. Miranda Jayne Toledano
Ms. Miranda Jayne Toledano
Independent Director
Independent Director
81.44K
-21.42%
Mr. Michael C. Pearce
Mr. Michael C. Pearce
Independent Director
Independent Director
10.00K
-471.73%
Ms. Jaclyn Jaffe
Ms. Jaclyn Jaffe
Investor Relations
Investor Relations
--
--
Mr. Justin Smith
Mr. Justin Smith
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Claude Maraoui
Mr. Claude Maraoui
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.29M
+10.02%
Mr. Ramsey Alloush
Mr. Ramsey Alloush
Chief Operating Officer, General Counsel
Chief Operating Officer, General Counsel
470.73K
+32.73%
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
330.44K
-14.36%
Mr. Joseph Benesch, CPA
Mr. Joseph Benesch, CPA
Chief Financial Officer, Corporate Controller
Chief Financial Officer, Corporate Controller
187.57K
+46.27%
Mr. Neil Herskowitz
Mr. Neil Herskowitz
Independent Director
Independent Director
81.44K
-21.42%
Ms. Miranda Jayne Toledano
Ms. Miranda Jayne Toledano
Independent Director
Independent Director
81.44K
-21.42%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Journey Medical Corp?
Los cinco principales accionistas de Journey Medical Corp son: Mr. Claude Maraoui
¿Cuántas instituciones poseen acciones de Journey Medical Corp (DERM)?
A fecha de 2026Q1, 137 instituciones poseen acciones de Journey Medical Corp, con un valor de mercado combinado de aproximadamente 12.08M, lo que representa el 56.62% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 2740272.00.
¿Cuál es la mayor fuente de ganancias de Journey Medical Corp?
El 2026Q1, el segmento empresarial Qbrexa generó la ganancia más alta para Journey Medical Corp, ascendiendo a 25.01M y representando el 40.85% de la ganancia total.